(Q43745676)

26 November 2017

title

CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. (English)

1 reference

26 November 2017

0 references

1 reference

Y Zhu

1

1 reference

26 November 2017

N Liu

2

1 reference

26 November 2017

S D Xiong

3

1 reference

26 November 2017

Y J Zheng

4

1 reference

26 November 2017

Y W Chu

5

1 reference

26 November 2017

publication date

1 April 2011

1 reference

Scandinavian Journal of Immunology

26 November 2017

published in

1 reference

26 November 2017

volume

73

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

301-308

1 reference

Chemistry and chemical biology of taxane anticancer agents.

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

TLR2 is expressed on activated T cells as a costimulatory receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Toll-like receptor ligands directly promote activated CD4+ T cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Toll-like receptor 2 controls expansion and function of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Are innate immune signaling pathways in plants and animals conserved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

Human CD4+ T Cells Express TLR5 and Its Ligand Flagellin Enhances the Suppressive Capacity and Expression of FOXP3 in CD4+CD25+ T Regulatory Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2011.02514.X

10.1111/J.1365-3083.2011.02514.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference